Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction

Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction

Yair Humberto González-Tuyub,1 Karla Daniela González-Iñiguez,1 Paula Catalina Lizarazo-Guiza,2 Sergio Ricardo García-García3 1Clinical Immunology and Allergy Service, ISSSTE Hospital Regional General, Ignacio Zaragoza, Ciudad de México, México; 2Medical Scientific Liaison, AstraZeneca, Ciudad de Mé...

Full description

Saved in:
Bibliographic Details
Main Authors: González-Tuyub YH, González-Iñiguez KD, Lizarazo-Guiza PC, García-García SR
Format: Article
Language:English
Published: Dove Medical Press 2024-11-01
Series:Journal of Asthma and Allergy
Subjects:
asthma
eosinophils
benralizumab
biologics
csi-laba therapy
Online Access:https://www.dovepress.com/benralizumab-effectiveness-in-patients-with-uncontrolled-severe-eosino-peer-reviewed-fulltext-article-JAA
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/benralizumab-effectiveness-in-patients-with-uncontrolled-severe-eosino-peer-reviewed-fulltext-article-JAA

Similar Items